Key result
High-dose statin therapy linked to a ~22% reduction in LAD coronary inflammation.
Why the study?
Perivascular FAI reflects coronary inflammation, but the effect of statin therapy on FAI had not been clearly demonstrated.
Does high-dose statin therapy reduce perivascular inflammation measured by FAI on CCTA in patients with coronary atheromatous plaques?
Population
23 patients with typical chest pain, low-to-intermediate CAD likelihood, and at least one coronary plaque on CCTA
Comparison
Follow-up vs baseline after long-term high-dose statin therapy
Design
Observational follow-up study
Follow-up
1.5 to 3 years
Authors
Loading...
Supports FAI as statin response marker; leaves open translation to cardiovascular outcomes.
Observational (n=23)
Does high-dose statin therapy reduce perivascular inflammation measured by FAI on CCTA in patients with coronary atheromatous plaques?
Absolute Event Rate: 12.4% vs 15.87%
p-value: p=0.04
Long-term high-dose statin therapy significantly reduces perivascular inflammation as measured by CCTA-derived FAI-score, particularly in the left anterior descending artery.
Matyas et al. (2023) conducted an observational in Coronary artery disease (n=23). High-dose statin therapy vs. Baseline (pre-treatment) was evaluated on Changes in perivascular FAI-score in the left anterior descending artery (p=0.04). High-dose statin therapy significantly reduced coronary inflammation, measured by the FAI-score in the left anterior descending artery, from 15.87 at baseline to 12.40 at follow-up (p=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: